9 results
In this mixed methods study, the main goals are to determine the effect of solution-focused brief therapy (SFBT) on quality of life (quantitative study) and to describe the influence of SFBT on the experiences, emotions and behaviors of the…
Primary ObjectivePart1: To evaluate the safety and tolerability of intravenous (IV) administration of AL001 over up to 96 weeks in asymptomatic and symptomatic carriersof a granulin (GRN) mutation causative of frontotemporal dementia (FTD) and in…
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the study drug CT1812 in subjects with mild to moderate Alzheimer*s disease. The efficacy of CT1812 will be compared to the efficacy of a placebo. A placebo is a…
The present study aims to address the limitations of earlier research, by employing a large sample size, and investigating the possibility that music therapy has an effect on wellbeing of people with dementia when using blinded outcome assessments…
The purpose of this research is to determine the usability of a wearable regarding the care of people with dementia showing challenging behaviour in a nursing home (geriatric psychiatry department). The relationship between biomedical data and…
The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Neuropsychological Test Battery (NTB) comprised of:*Cogstate Detection test (DET)*Cogstate Identification test (IDN)*Cogstate One…
The present study aims to investigate whether a standardized 8-week group MBSR treatment can significantly reduce symptoms of stress, anxiety and depression, and improve quality of life in at-risk mutation carriers for FTD. The primary objective is…
This study has been transitioned to CTIS with ID 2024-515198-91-00 check the CTIS register for the current data. To assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an…
The objectives of the study are to: • Assess the efficacy of 2 dose levels of COR388 HCl in Alzheimer*s disease (AD) subjects; and• Assess the safety and tolerability of 2 dose levels of COR388 HCl in AD subjects.